Novo Nordisk | NVO - Interest Expense On Debt


Novo Nordisk reported DKK82.1M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Aurora Cannabis CAD 230K 1.88M Mar/2026
Bausch Health Companies USD 402M 5M Mar/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
GlaxoSmithKline GBP 121M 46M Jun/2026
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 462M 119M Jun/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Pacira USD 3.62M 77K Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 10.67M 636K Dec/2025
Sanofi EUR 287M 109M Jun/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Zoetis USD 62M 5M Mar/2026